Literature DB >> 17293489

Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in rat ventricular myocardium.

Maria Pia Gallo1, Renzo Levi, Roberta Ramella, Alessia Brero, Ombretta Boero, Bruno Tota, Giuseppe Alloatti.   

Abstract

Vasostatins (VSs) are vasoactive peptides derived from chromogranin A (CgA), a protein contained in secretory granules of chromaffin and other cells. The negative inotropic effect and the reduction of isoproterenol (Iso)-dependent inotropism induced by VSs in the heart suggest that they have an antiadrenergic function. However, further investigation of the mechanisms of action of VSs is needed. The aim of the present study was to define the signaling pathways activated by VS-1 in mammalian ventricular myocardium and cultured endothelial cells that lead to the modulation of cardiac contractility. Ca(2+) and nitric oxide (NO) fluorometric confocal imaging was used to study the effects induced by recombinant human VS-1 [STA-CgA-(1-76)] on contractile force, L-type Ca(2+) current, and Ca(2+) transients under basal conditions and after beta-adrenergic stimulation in rat papillary muscles and ventricular cells and the effects on intracellular Ca(2+) concentration and NO production in cultured bovine aortic endothelial (BAE-1) cells. VS-1 had no effect on basal contractility of papillary muscle, but the effect of Iso stimulation was reduced by 27%. Removal of endocardial endothelium and inhibition of NO synthesis and phosphatidylinositol 3-kinase (PI3K) activity abolished the antiadrenergic effect of VS-1 on papillary muscle. In cardiomyocytes, 10 nM VS-1 was ineffective on basal and Iso (1 microM)-stimulated L-type Ca(2+) current and Ca(2+) transients. In BAE-1 cells, VS-1 induced a Ca(2+)-independent increase in NO production that was blocked by the PI3K inhibitor wortmannin. Our results suggest that the antiadrenergic effect of VS-1 is mainly due to a PI3K-dependent NO release by endothelial cells, rather than a direct action on cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17293489     DOI: 10.1152/ajpheart.01253.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

Review 1.  Non-pharmacological, non-ablative approaches for the treatment of atrial fibrillation: experimental evidence and potential clinical implications.

Authors:  Benjamin J Scherlag; Hiroshi Nakagawa; Warren M Jackman; Ralph Lazzara; Sunny S Po
Journal:  J Cardiovasc Transl Res       Date:  2010-11-06       Impact factor: 4.132

Review 2.  Cardiomyokines from the heart.

Authors:  Ayano Chiba; Haruko Watanabe-Takano; Takahiro Miyazaki; Naoki Mochizuki
Journal:  Cell Mol Life Sci       Date:  2017-12-13       Impact factor: 9.261

Review 3.  The Role of the Atrial Neural Network In Atrial Fibrillation: The Metastatic Progression Hypothesis.

Authors:  X Shen; B J Scherlag; B He; J Sun; G Mei; S S Po
Journal:  J Atr Fibrillation       Date:  2013-08-31

4.  Adrenal gland-released vasostatin-I is a myocardial depressant factor.

Authors:  Francis Schneider; Vincent Castelain; Jean-Etienne Herbrecht; Sophie Hellé; Marie-Hélène Metz-Boutigue
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

5.  The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac β-adrenergic-like inotropes.

Authors:  Bruno Tota; Stefano Gentile; Teresa Pasqua; Eleonora Bassino; Hisatsugu Koshimizu; Niamh X Cawley; Maria C Cerra; Y Peng Loh; Tommaso Angelone
Journal:  FASEB J       Date:  2012-03-29       Impact factor: 5.191

6.  Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines.

Authors:  Mark J Shen; Tetsuji Shinohara; Hyung-Wook Park; Kyle Frick; Daniel S Ice; Eue-Keun Choi; Seongwook Han; Mitsunori Maruyama; Rahul Sharma; Changyu Shen; Michael C Fishbein; Lan S Chen; John C Lopshire; Douglas P Zipes; Shien-Fong Lin; Peng-Sheng Chen
Journal:  Circulation       Date:  2011-05-09       Impact factor: 29.690

7.  A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3K-eNOS pathway in the myocardium.

Authors:  Eleonora Bassino; Sara Fornero; Maria Pia Gallo; Roberta Ramella; Sushil K Mahata; Bruno Tota; Renzo Levi; Giuseppe Alloatti
Journal:  Cardiovasc Res       Date:  2011-05-04       Impact factor: 10.787

Review 8.  Chromogranin A: a novel susceptibility gene for essential hypertension.

Authors:  Bhavani S Sahu; Parshuram J Sonawane; Nitish R Mahapatra
Journal:  Cell Mol Life Sci       Date:  2009-11-27       Impact factor: 9.261

9.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

10.  Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart.

Authors:  Rosa Mazza; Alfonsina Gattuso; Cinzia Mannarino; Bhawanjit K Brar; Sandra Francesca Barbieri; Bruno Tota; Sushil K Mahata
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-09       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.